Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis (Q36581066)

15 August 2017

1 reference

title

Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

1 reference

Bertrand Coiffier

1

1 reference

15 August 2017

publication date

1 August 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

24

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

548-552

1 reference

Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Reactivation of hepatitis b after transplantation operations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Reactivation of hepatitis B virus with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

State-of-the-art therapeutics: diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Fatal hepatic failure secondary to acute herpes simplex virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Acute hepatic injury after discontinuation of chemotherapy in a patient with non-Hodgkin's lymphoma and chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Hepatitis B virus reactivation after kidney transplantation and new onset lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Hepatitis B virus reactivation during fludarabine therapy in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Acute exacerbation of chronic hepatitis B during thalidomide therapy for multiple myeloma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Molecular adsorbent recirculating system treatment for acute hepatic failure in patients with hepatitis B undergoing chemotherapy for non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

Lamivudine treatment in a patient with hepatitis B virus reactivation after allogenic peripheral bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600815232

10.1080/07357900600815232

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference